Literature DB >> 2464158

Endothelium-mediated coronary dilatation by adenosine does not depend on endothelial adenylate cyclase activation: studies in isolated guinea pig hearts.

W H Newman1, B F Becker, M Heier, S Nees, E Gerlach.   

Abstract

Adenosine, applied to the coronary system of guinea pigs at up to 10(-6) M, elicits dilatation solely via an endothelium-mediated process. We investigated the role of coronary A2 receptors in this dilation, since the coronary endothelium possesses adenosine A2-receptors with a stimulatory action on the adenylate cyclase. In situ, A2 receptor stimulation can be assessed by prelabeling the coronary endothelial adenine nucleotide pool with 3H-adenosine and subsequently determining the rate of release of radiolabeled cAMP induced by A2 agonists. Thus, perfusion of isolated hearts with 5'-N-ethylcarboxamidoadenosine (NECA) dose-dependently increased coronary flow and the release of 3H-cAMP from the endothelium. In the presence of 50 microM 2',5'-dideoxyadenosine (ddA), a P-site agonist which inhibits the catalytic activity of adenylate cyclase, coronary flow increases induced by both adenosine and NECA were unaffected. In contrast, ddA reduced the release of labeled cAMP in response to NECA by about 60%. In cultured endothelial cells, ddA likewise inhibited cAMP accumulation due to NECA by about 70%. Moreover, ddA antagonized the adenylate cyclase mediated flow response due to the PGI2 analogue, iloprost, as well as the positive chronotropic and inotropic actions of isoproterenol. The dissociation elicited by ddA between the coronary flow response and the release of cAMP strongly indicates that the endothelial A2 receptors which are linked to adenylate cyclase are not causally involved in endothelium-dependent coronary dilatation induced by adenosine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2464158     DOI: 10.1007/bf00581221

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  30 in total

Review 1.  Role of endothelium in responses of vascular smooth muscle.

Authors:  R F Furchgott
Journal:  Circ Res       Date:  1983-11       Impact factor: 17.367

2.  Capillary transport of adenosine.

Authors:  H V Sparks; D F DeWitt; R D Wangler; M W Gorman; J B Bassingthwaighte
Journal:  Fed Proc       Date:  1985-07

3.  Isolation, identification, and continuous culture of coronary endothelial cells from guinea pig hearts.

Authors:  S Nees; A L Gerbes; E Gerlach; J Staubesand
Journal:  Eur J Cell Biol       Date:  1981-06       Impact factor: 4.492

4.  PGI2 enhanced cAMP content in bovine coronary arteries in the presence of isobutylmethylxanthine.

Authors:  A Dembinska-Kiec; W Rücker; P S Schönhöfer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-08       Impact factor: 3.000

5.  Extracellular ATP activates polyphosphoinositide breakdown and Ca2+ mobilization in Ehrlich ascites tumor cells.

Authors:  G R Dubyak
Journal:  Arch Biochem Biophys       Date:  1986-02-15       Impact factor: 4.013

6.  Relationship between myocardial oxygen consumption, coronary flow, and adenosine release in an improved isolated working heart preparation of guinea pigs.

Authors:  H Bardenheuer; J Schrader
Journal:  Circ Res       Date:  1983-03       Impact factor: 17.367

7.  Acute effects of nicotine on hemodynamic and metabolic parameters of isolated, perfused hearts of guinea pigs and rats.

Authors:  B F Becker; E Gerlach
Journal:  Klin Wochenschr       Date:  1984

8.  Ulex europaeus I lectin as a marker for vascular endothelium in human tissues.

Authors:  H Holthöfer; I Virtanen; A L Kariniemi; M Hormia; E Linder; A Miettinen
Journal:  Lab Invest       Date:  1982-07       Impact factor: 5.662

9.  Effects of PGI2 and PGI analogues on cAMP levels in cultured endothelial and smooth muscle cells derived from bovine arteries.

Authors:  A Dembinska-Kiec; W Rücker; P S Schönhöfer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-02       Impact factor: 3.000

10.  Regulation of the catalytic component of adenylate cyclase. Potentiative interaction of stimulatory ligands and 2',5'-dideoxyadenosine.

Authors:  V A Florio; E M Ross
Journal:  Mol Pharmacol       Date:  1983-09       Impact factor: 4.436

View more
  7 in total

1.  Role of ω-hydroxylase in adenosine-mediated aortic response through MAP kinase using A2A-receptor knockout mice.

Authors:  Dovenia S Ponnoth; Mohammed A Nayeem; Swati S Kunduri; Stephen L Tilley; Darryl C Zeldin; Catherine Ledent; S Jamal Mustafa
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-07       Impact factor: 3.619

2.  CYP-epoxygenases contribute to A2A receptor-mediated aortic relaxation via sarcolemmal KATP channels.

Authors:  Dovenia S Ponnoth; Mohammed A Nayeem; Stephen L Tilley; Catherine Ledent; S Jamal Mustafa
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-09-26       Impact factor: 3.619

3.  Functional characterization of coronary vascular adenosine receptors in the mouse.

Authors:  A Flood; J P Headrick
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

Review 4.  It is time to ask what adenosine can do for cardioprotection.

Authors:  M Kitakaze; M Hori
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

5.  Myocardial adenosine stimulates release of cyclic adenosine monophosphate from capillary endothelial cells in guinea pig heart.

Authors:  K Kroll; J Schrader
Journal:  Pflugers Arch       Date:  1993-05       Impact factor: 3.657

6.  Absence of adenosine-mediated aortic relaxation in A(2A) adenosine receptor knockout mice.

Authors:  Dovenia S Ponnoth; Maryam Sharifi Sanjani; Catherine Ledent; Kevin Roush; Thomas Krahn; S Jamal Mustafa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-11       Impact factor: 4.733

7.  Adenosine relaxation in isolated rat aortic rings and possible roles of smooth muscle Kv channels, KATP channels and A2a receptors.

Authors:  Aryadi Arsyad; Geoffrey P Dobson
Journal:  BMC Pharmacol Toxicol       Date:  2016-05-23       Impact factor: 2.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.